THR-Beta Agonist Dosing Guided by SHBG for LDL-C Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for non-alcoholic steatohepatitis (NASH) and lipid disorders such as hypercholesterolemia are inadequate, with many patients not achieving desired LDL-C levels despite existing therapies, and there is a need for personalized dosing strategies to improve treatment efficacy.
Innovation Solution
A method involving a thyroid hormone receptor-beta agonist, 2-(3,5-dichloro-4-((5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile (Compound A), is administered in personalized doses based on biomarker tests and genetic profiling to treat lipid disorders, adjusting dosing based on sensitivity and demographic factors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If standard lipid-lowering therapies (statins, ezetimibe, PCSK9 inhibitors) are administered to HeFH patients, then some LDL-C reduction is achieved, but approximately 81% of patients do not reach target LDL-C levels
Solution Approach 1:
The patent applies parameter changes by transitioning from conventional lipid-lowering mechanisms (HMG-CoA reductase inhibition, cholesterol absorption blockade, PCSK9 inhibition) to a novel THR-beta agonist mechanism that upregulates LDL receptor expression. This fundamental parameter change in the therapeutic mechanism enables achieving target LDL-C levels in HeFH patients who failed to respond to standard therapies, directly addressing the 81% treatment failure rate.
2Reliability
If personalized dosing based on SHBG biomarker testing is implemented, then treatment efficacy is improved, but treatment complexity and cost increase
Solution Approach 1:
The patent implements preliminary action by performing SHBG biomarker testing before initiating Compound A treatment. This pre-treatment assessment allows clinicians to identify patients with higher sensitivity to Compound A (those with lower baseline SHBG levels) and tailor the dosing strategy accordingly. By performing this biomarker assessment in advance, the treatment protocol becomes more efficient and targeted, reducing the need for extensive trial-and-error dose adjustments during treatment.
Solution Approach 2:
The patent applies feedback by using SHBG biomarker levels to guide dosing decisions. Patients with lower baseline SHBG levels (indicating higher sensitivity) receive lower initial doses, while those with higher SHBG levels receive higher doses. This feedback-driven approach optimizes treatment efficacy while minimizing side effects, and the patent specifically notes that this personalized approach may reduce the need for frequent dose adjustments during treatment.
3Manufacturing precision
If higher doses of Compound A are administered to achieve better lipid control, then LDL-C reduction improves, but risk of adverse effects increases
Solution Approach 1:
The patent applies parameter changes by utilizing SHBG biomarker levels as a sensitivity indicator to determine optimal dosing parameters. By measuring baseline SHBG levels and using this information to select appropriate doses, the treatment achieves effective LDL-C reduction while avoiding excessive dosing that could cause adverse effects. This parameter-based dosing strategy directly addresses the balance between efficacy and safety.
Solution Approach 2:
The patent implements self-service by using the patient's own SHBG biomarker levels to guide dosing decisions. The body's natural response to Compound A (reflected in SHBG levels) serves as the basis for determining the appropriate dose, eliminating the need for extensive trial-and-error dosing and reducing the risk of adverse effects from inappropriate dosing.
Data Source
Figure 1
Figure 2A
Figure 2B
AI summary
The present invention provides a method for treating a liver disorder or lipid disorder in a subject in need thereof with 2-(3,5-dichloro-4-((5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile, a stereoisomer, a salt thereof, or a morphic form thereof.